Indian Pharmaceutical Alliance (IPA) Announces New Office Bearers

Indian Pharmaceutical Alliance announced on Monday, October 04, 2021 the appointment of Mr Samir Mehta, Chairman of Torrent Group as President of the IPA for 2021-2023 and Ms Samina Hamied, Executive Vice Chairperson, Cipla as the new Vice President.

Mr. Samir Mehta is the Chairman of Torrent Group of companies. Torrent is one of India’s fast growing and well-respected Pharma majors. Torrent has taken several strategic initiatives, including acquisitions, forays into new therapies and geographies, large investments in product development infrastructure and capabilities, building state-of-the-art manufacturing facilities.

Speaking on the new role, Mr. Mehta said, “COVID 19 has been a challenging time for the Indian pharmaceutical industry. However, the industry has risen to the challenges and ensured continuous supply of medicines to patients. The pandemic has further highlighted the significance of collaboration, access to affordable medicines and innovation to respond to the country’s healthcare needs. IPA will be collaborating with stakeholders to strengthen the accessibility of medicines and help in creating an innovation ecosystem that will be beneficial to the patients.”

Ms Samina Hamied is the Executive Vice Chairperson of Cipla and represents the third generation of the founding family of Cipla. Cipla is a leading global pharmaceutical company with 46 manufacturing sites around the world that produce 50+ dosage forms and 1,500+ products that cater to 80+ markets. Cipla’s strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. It is ranked 3rd largest in pharma in India and 3rd largest in the pharma private market in South Africa and is amongst the top ten most dispensed generic players in the U.S. Ms. Hamied said “Pleased to receive this opportunity to play a pivotal role in shaping the healthcare ecosystem and unlocking significant growth opportunities. I am looking forward to working collaboratively with all stakeholders of the industry to ensure sustainable, resilient and agile operations and create a positive difference in the lives of patients.”

Sudarshan Jain, Secretary General, IPA, states “At this unprecedented time of COVID-19 pandemic when pharmaceutical industry is undergoing a crucial phase of its growth and development, IPA will continue to play a vital role in realising the Industry Vision 2030 of being the largest producer of medicines in the world in volume and move up the value chain with focus on research and development.”

Indian Pharmaceutical Alliance (IPA) represents 23 research based national pharmaceutical companies. Collectively, IPA companies account for over 85 per cent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country’s exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market. For any further queries please contact: Ms. Archana Jatkar at Email: archana.jatkar@ipa-india.org